Amid market uncertainty, deal volumes and values in 2019 fell slightly, with activity supported by mega-deals in Pharmaceuticals, high levels of Private Equity dry powder and a large number of focused acquisitions. Especially in uncertain times, a seamless integration is key to adding shareholder value.
So near and yet so far. For a moment towards the end of 2019, a surge in transactions made it seem possible that last year might break 2018’s record achievement for highest deal numbers and values. In the end, 2019 deal volumes and values fell slightly short. This is in itself a remarkable achievement given the heightened uncertainties we’ve seen over the past twelve months.